N/A
Completed N=400
Behavioral Economics Trial To Enhance Regulation of Blood Pressure (BETTER-BP)
High Blood Pressure
Source: ClinicalTrials.gov NCT04114669 ↗
Enrolled (actual)
400
Serious AEs
11.0%
Results posted
May 2026
Primary outcomePrimary: Change in Systolic Blood Pressure (SBP) — -6.7; -5.8 mmHg
Summary
BETTER-BP (Behavioral Economics Trial To Enhance Regulation of Blood Pressure) is a phase II, single-center, prospective, pragmatic randomized clinical trial within the New York City Health and Hospitals (NYC-H+H) system and NYU Langone Family Health Centers. The trial will recruit from 3 NYC-H+H ambulatory clinics as well as NYU Langone Family Health Centers, and will use a lottery incentive program to promote adherence to antihypertensive medication that will be delivered via smartphone for 6 months. The trial will randomize 435 patients with hypertension determined to have poor adherence (<80% adherence with antihypertensive medication), in a 2:1 (intervention:control) ratio. Baseline enrollment will occur over 36 months with an expected 12 months follow-up per participant.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Systolic Blood Pressure (SBP) |
-0.2; 3.6 | — |
| SECONDARY Percentage of Participants With Adequate Antihypertensive Adherence |
31; 26 | — |
Eligibility Criteria
Inclusion Criteria
- A diagnosis of hypertension.
- An active prescription for ≥1 antihypertensive medication (any of the following classes: thiazide diuretic, ACE inhibitor, angiotensin receptor blocker, beta blocker, calcium channel blocker, centrally acting alpha agonist, direct vasodilator).
- 1 ambulatory systolic blood pressure ≥140 mmHg (on therapy).
- Suboptimal adherence (self-report).
Exclusion Criteria
- Incarcerated
- Pregnant
- Unable to use study software (Way To Health) in English or Spanish
- Unable/unwilling to consent
- Clear barrier to technology use (e.g. visual or hearing impairment)
- Projected life expectancy <12 months
Data sourced from ClinicalTrials.gov (NCT04114669). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.